Matches in Wikidata for { <http://www.wikidata.org/entity/Q95277372> ?p ?o ?g. }
Showing items 1 to 40 of
40
with 100 items per page.
- Q95277372 description "article scientifique publié en 2020" @default.
- Q95277372 description "artículu científicu espublizáu en mayu de 2020" @default.
- Q95277372 description "scientific article published on 19 May 2020" @default.
- Q95277372 description "wetenschappelijk artikel" @default.
- Q95277372 description "наукова стаття, опублікована 19 травня 2020" @default.
- Q95277372 name "Correction to: Development of Nanocrystal Ziprasidone Orally Disintegrating Tablets: Optimization by Using Design of Experiment and In Vitro Evaluation" @default.
- Q95277372 name "Correction to: Development of Nanocrystal Ziprasidone Orally Disintegrating Tablets: Optimization by Using Design of Experiment and In Vitro Evaluation" @default.
- Q95277372 type Item @default.
- Q95277372 label "Correction to: Development of Nanocrystal Ziprasidone Orally Disintegrating Tablets: Optimization by Using Design of Experiment and In Vitro Evaluation" @default.
- Q95277372 label "Correction to: Development of Nanocrystal Ziprasidone Orally Disintegrating Tablets: Optimization by Using Design of Experiment and In Vitro Evaluation" @default.
- Q95277372 prefLabel "Correction to: Development of Nanocrystal Ziprasidone Orally Disintegrating Tablets: Optimization by Using Design of Experiment and In Vitro Evaluation" @default.
- Q95277372 prefLabel "Correction to: Development of Nanocrystal Ziprasidone Orally Disintegrating Tablets: Optimization by Using Design of Experiment and In Vitro Evaluation" @default.
- Q95277372 P1433 Q95277372-2D636BAF-3829-4374-94C9-8833FA43D31D @default.
- Q95277372 P1476 Q95277372-3C2D6F9E-B623-47F9-AF4C-995E43DD3171 @default.
- Q95277372 P2093 Q95277372-3D9AE2F5-03D5-4E6C-B273-FBBE41A6F91F @default.
- Q95277372 P2093 Q95277372-B58A5D36-03BA-4590-B51D-355814EBC8F4 @default.
- Q95277372 P2093 Q95277372-E9B49EBB-92BB-4F9E-910D-210FBAA00C8D @default.
- Q95277372 P304 Q95277372-5EE5520C-18C6-42FE-8F40-DBE8948E0F8B @default.
- Q95277372 P31 Q95277372-5E1B8113-806A-4A9E-BCA0-7917B9B24A72 @default.
- Q95277372 P31 Q95277372-91F3DD46-4474-4D58-88EA-7DE3DB353317 @default.
- Q95277372 P356 Q95277372-6F3609D9-1417-45DF-9CD0-F7D0F20088FF @default.
- Q95277372 P433 Q95277372-94280240-705D-47DF-B13B-BBC1BEF241DF @default.
- Q95277372 P478 Q95277372-CA719EB8-9F18-4115-AF91-5C3617101599 @default.
- Q95277372 P577 Q95277372-2A5F3289-DF59-40B9-9AEA-791412755042 @default.
- Q95277372 P698 Q95277372-11730D49-2D73-4D1B-AE5F-E1D1C6E51AA7 @default.
- Q95277372 P356 S12249-020-01703-2 @default.
- Q95277372 P698 32430673 @default.
- Q95277372 P1433 Q15750612 @default.
- Q95277372 P1476 "Correction to: Development of Nanocrystal Ziprasidone Orally Disintegrating Tablets: Optimization by Using Design of Experiment and In Vitro Evaluation" @default.
- Q95277372 P2093 "Alptug Karakucuk" @default.
- Q95277372 P2093 "Emine Tashan" @default.
- Q95277372 P2093 "Nevin Celebi" @default.
- Q95277372 P304 "144" @default.
- Q95277372 P31 Q13442814 @default.
- Q95277372 P31 Q1348305 @default.
- Q95277372 P356 "10.1208/S12249-020-01703-2" @default.
- Q95277372 P433 "5" @default.
- Q95277372 P478 "21" @default.
- Q95277372 P577 "2020-05-19T00:00:00Z" @default.
- Q95277372 P698 "32430673" @default.